Recursion (RXRX) announced the top-line results from the SYCAMORE trial, a Phase 2, 12-month, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and exploratory efficacy of REC-994 in patients with symptomatic Cerebral Cavernous Malformation. The trial achieved its primary endpoint, demonstrating that REC-994 had a comparable safety and tolerability profile to the placebo, with similar frequencies and severities of adverse events observed across the placebo, 200mg, and 400mg dosage arms over the 12-month treatment period.
Recursion plans to present the trial data at an upcoming medical conference and aims to submit the findings for publication in a peer-reviewed scientific journal.
